Prechallenge high neutralizing antibodies and long-lasting immune reactivity to gp41 correlate with protection of rhesus monkeys against productive simian immunodeficiency virus infection or disease development

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 19, Issue 5, 1998, Pages 441-450

  Petry, Harald ^a   Dittmer, Ulf ^a   Jones, David ^b   Farrar, Graham ^b   Wachter, Helmut ^c   Fuchs, Dietmar ^c   Nißlein, Thomas ^a   Jurkiewicz, Elke ^a   Hunsmann, Gerhard ^a   Stahl Hennig, Christiane ^a   Lüke, Wolfgang ^a  

^a GERMAN PRIMATE CENTER   (Germany)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

gp130 oligomers; Neutralization; Rhesus monkeys; SIVmac32H; Vaccine protection

Indexed keywords

GLYCOPROTEIN GP 130; GLYCOPROTEIN GP 41; KEYHOLE LIMPET HEMOCYANIN; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; DISEASE COURSE; DRUG EFFICACY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANIMALIA; MACACA MULATTA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0032535598     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199812150-00002     Document Type: Article

References (38)

1. Alter HJ, Eichberg J, Masur H, et al. Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS. Science 1984;226:549-52.
2. Stahl-Hennig C, Herchenröder O, Nick S, et al. Experimental infection of macaques with HIV-2ben, a novel HIV-2 isolate. AIDS 1990;4:611-7.
3. Daniel MD, Letvin N, King NW, et al. Isolation of T-cell tropic HTLV-III-like retrovirus from macaques. Science 1985;228: 1200-4.
4. Li J, Haseltine W, Letvin N, et al. Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J AIDS 1992;5:639-46.
5. Letvin N, Daniel MD, Sehgal P, et al. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus from San Francisco patients with AIDS. Science 1985;225:840-42.
6. Reimann K, Li J, Veazey R, et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J Virol 1996;70:6922-8.
7. Israel Z, Edmonson P, Maul D, et al. Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994;68:1843-53.
8. Lüke W, Voss G, Stahl-Hennig C, et al. Protection of cynomolgous macaques against infection by the human immunodeficiency virus type 2 strain ben (HIV-2ben) through immunization with the virion-derived envelope glycoprotein gp130. AIDS Res Hum Retroviruses 1993;9:387-94.
9. Lüke W, Coulibaly C, Dittmer U, et al. Simian immunodeficiency virus (SIV) gp130-oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo. Virology 1996;216:444-50.
10. Giavedoni L, Planelles V, Haighwood N, et al. Immune response of rhesus macaques to recombinant SIV gp130 does not protect from challenge infection. J Virol 1993;67:577-83.
11. Mills K, Page M, Chan W, et al. Protection against SIV infection in macaques by immunization with inactivated virus from the 28 molecular clone, but not with the BK28-derived recombinant env and gag proteins. J Med Primat 1992;21:50-7.
12. Ahmad S, Lohmann B, Marthas M, et al. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10:195-204.
13. Ohkawa S, Wilson L, Larosa G, et al. Immune response induced by prototype vaccines for AIDS in rhesus monkeys. AIDS Res Hum Retroviruses 1994;10:27-38.
14. Hulskotte E, Geretti A, Siebelink K, et al. Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J Virol 1995;69:6289-96.
15. Hu SL, Abrams K, Barber GN, et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-9.
16. Myagkikh M, Alipanam S, Markham P, et al. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses 1996;12:985-92.
17. Mossman S, Bex F, Berglund P, et al. Protection against lethal simian immunodeficiency virus SIVsmmPBJ14 disease by recombinant semliki forest virus gp160 vaccine and by a gp120 subunit vaccine. J Virol 1996;70:1953-60.
18. Letvin N, Montefiori D, Yasutomi Y, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci 1997;94:9378-83.
19. Lehner T, Wang Y, Cranage M, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996;2:767-75.
20. Salahuddin SZ, Markham PD, Wong-Staal F, et al. Restricted expression of human T-cell leukemia - lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology 1983;129:51-64.
21. Sodroski JG, Goh WC, Rosen CA, et al. trans-Activation of the human T-cell leukemia virus long terminal repeat correlates with expression of the x-loc protein. J Virol 1985;55:831-5.
22. Giljam G, Siridewa K, Hammar L. Purification of simian immunodeficiency virus, SIVmac251, and of its external envelope glycoprotein, gp148. J Chromatography 1994;675:89-100.
23. Jones D, McBride B, Roff M, Maloney V, Farrar G. Purification and characterization of simian immunodeficiency virus (SIVmac) envelope glycoprotein gp130 from virus-infected cells. Vaccine 1994;12:250-8.
24. Lüke W, Stahl-Hennig C, Nick S, et al. Immunization of rhesus monkeys with Tween-ether treated SIV protects against experimental SIV infection. In: Ginsberg H, Brown F, Lerner RA, Chanock RM, eds. Vaccines 92: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1992:103-8.
25. Stahl-Hennig C, Voss G, Dittmer U, et al. Protection of monkeys by a split vaccine against SIVmac depends upon biological properties of the challenge virus. AIDS 1993;7:1-9.
26. Harada S, Purtilo D, Koyangi Y, Sonnabend J, Yamamoto N. Sensitive assay for neutralizing antibodies against AIDS-related viruses (HTLV-III/LAV). J Immunol Methods 1986;92:177-81.
27. Jurkiewicz E, Hunsmann G, Schäffner J, et al. Identification of the V1 region as a linear neutralizing epitope of the simian immunodeficiency virus SIVmac envelope glycoprotein. J Virol 1997;71: 9475-81.
28. Polzien F, Scharf J, Lüke W, Hunsmann G. CD4-binding of gp130 micelles isolated from SIVagmTYO-7. AIDS Res Hum Retroviruses 1992;8:1171-7.
29. Dittmer U, Stahl-Hennig C, Coulibaly C, et al. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge. J Gen Virol 1995;76:1307-15.
30. Fendrich C, Lüke W, Stahl-Hennig C, et al. Urinary neopterin concentrations in rhesus monkeys after infection with simian immunodeficiency virus strain 251. AIDS 1989;3:305-7.
31. Jurkiewicz E, Petry H, Schäffner J, et al. Localization of a neutralization epitope in the V1 region of the SIVmac251 envelope. In: Ginsberg H, Brown F, Lerner RA, Chanock RM, eds. Vaccines 96: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1996:243-8.
32. Stott EJ. Anti-cell antibody in macaques. Nature 1991;353:393.
33. Cranage M, Polyanskaya N, McBride B, et al. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses 1993;9:13-22.
34. Sodroski J, Goh W, Rosen C, et al. Trans-activation of the human T-cell leukemia virus long terminal repeat correlates with expression of the x-lor protein. J Virol 1985;55:831-5.
35. Moore J, Sattentau Q, Yoshiyama H, et al. Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: human immune response to the V1 and V2 domain. J Virol 1993; 67:6136-51.
36. Moore J, Sattentau Q, Wyatt R, Sodroski J. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies. J Virol 1994;68: 469-84.
37. Earl P, Broder C, Long D, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivity. J Virol 1994;68:3015-26.
38. Sattentau Q, Moore J. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 1995;182:185-96.